INFEZIONI MICOTICHE IN PAZIENTI AFFETTI DA LEUCEMIA ACUTa MIELOIDE VALUTAZIONE CLINICO-MICROBIOLOGICA DI UN PROTOCOLLO DI PROFILASSI ANTIMICOTICA

30 Patients with Acute Myeloid Leukemia (AML), receiving chemotherapy to remission induction randomized, were to receive (Group A) or not (Group B) oral Amphotericin B in tablets, as a prophylaxis against oral and/or gastrointestinal candidiasis. The authors, in fact, used a new preparation (slowly chewing tablets) which allows a more prolonged permanence of the active principle at the level of the throat than the suspension. By the meaning of the results, it was shown that only 2 out 15 patients in the Group A, treated with Amphotericin B, developped oral candidiasis, without intestinal colonization. In the Group B, on the contrary, oral candidiasis was shown in 7 out of 13 patients. The Minimal Inhibitory Concentration of Amphotericin B against the isolated strains was evaluated. At the same time, the specific antibody titres of the patients with proved mycotic infection were evaluated by the authors.